Vion Pharmaceuticals, Inc.
(Public, OTC:VION) Watch this stockFind more results for
vion
Advertisement
Events
Nov 12, 2009
Q3 2009 Conference Call -
Nov 10, 2009
Q3 2009 Release
|
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -132280.00% | -69413.95% |
| Operating margin | -98980.00% | -58355.81% |
| EBITD margin | - | -57579.07% |
| Return on average assets | -90.76% | -58.14% |
| Return on average equity | - | - |
| Employees | 43 | - |
Address
Website links
Vion Pharmaceuticals, Inc. discussed on blogs
Top 50 Pharmaceutical Companies : Health Freedom Alliance
- vermont
- Health Freedom Alliance
- 16 hours ago
Vion Pharmaceuticals, Inc. discussions
View all discussions »Description
Vion Pharmaceuticals, Inc. (Vion) is a development-stage pharmaceutical company that develops therapeutics for the treatment of cancer. The Company has two small molecule anticancer agents in clinical development, which includes Onrigin (Laromustine)and Triapine. The Company also has two anticancer agents in the clinical development-stage. In February 2009, the Company filed a New Drug Application (NDA) for Onrigin with the United States Food and Drug Administration (FDA).
Officers and directors
| William R. Miller | Chairman of the Board | |
| Alan Kessman | Chief Executive Officer, Director | |
| Howard B. Johnson | President, Chief Financial Officer | |
| Karen Schmedlin | Vice President - Finance, Chief Accounting Officer, Secretary | |
| Ann Lee Cahill | Vice President - Clinical Development | |
| James Tanguay Ph.D. | Vice President - Chemistry, Manufacturing and Control | |
| William F. Hahne M.D. | Vice President - Medical | |
| Tanya Lewis | Vice President - Regulatory Affairs and Quality Assurance | |
| Ivan King Ph.D. | Vice President - Research & Development | |
| Alan C. Sartorelli Ph.D. | Director |
